The Role of Furosemide Stress Test in the Intensive Care Clinic

Launched by GULHANE TRAINING AND RESEARCH HOSPITAL · Jan 2, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a test called the furosemide stress test (FST) to see if it can help predict the progression of acute kidney injury (AKI) in patients who are critically ill and in the intensive care unit (ICU). AKI can lead to serious health problems and longer hospital stays, so finding ways to detect it earlier and manage it more effectively is very important. The researchers want to find out if this noninvasive test can help determine if patients will need more intensive treatments, like dialysis, to support their kidneys.

To participate in this study, patients must be over 18 years old and meet certain criteria related to their kidney function in the first 24 hours after being admitted to the ICU. This includes having a specific stage of AKI and enough fluid in their body. However, patients who are pregnant, have severe kidney issues, or are in need of urgent kidney treatments are not eligible. Those who join the study can expect to undergo the FST, which involves administering a medication to see how their kidneys respond. Overall, this trial aims to improve care for patients with AKI by providing better tools for predicting their health outcomes.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Those who meet KDIGO AKI stage 1 and stage 2 criteria in the first 24 hours
• • 2. Those with sufficient fluid volume (CVP≥6 cmH20)
• • 3. Female and male patients over the age of 18 will be included in the study
• Exclusion Criteria:
• • 1. Pregnant patients
• • 2. Hospitalization due to intoxication
• • 3. Liver or kidney transplant
• • 4. Glomerular filtration rate below 30 ml/min/1.73m2
• • 5. Active bleeding
• • 6. Patients with obstructive uropathy
• • 7. Patients in need of urgent RRT (K≥6.6 meq/L, pH\<7.15, pulmonary edema due to fluid overload, uremic complications)
• • 8. Patients evaluated as KDIGO AKI stage 3
• • 9. Patients who have received RRT in the last 30 days
• • 10. Patients with CKD diagnosis
• • 11. Patients with pulmonary embolism
• • 12. Hypoalbuminemia≥2.5 g/dl,
• • 13. Patients receiving cephalosporin treatment will be excluded from the sample.